Transdermal selegiline (Emsam)

Med Lett Drugs Ther. 2006 May 22;48(1235):41-2.
No abstract available

MeSH terms

  • Administration, Cutaneous
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / therapeutic use*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Interactions
  • Humans
  • Major Depressive Disorder / drug therapy*
  • Monoamine Oxidase Inhibitors / adverse effects
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Parkinson Disease / drug therapy*
  • Selegiline / adverse effects
  • Selegiline / therapeutic use*

Substances

  • Antiparkinson Agents
  • Monoamine Oxidase Inhibitors
  • Selegiline